Oragenics Inc (OGEN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Oragenics reported revenue of $0. Net income was -$9.8M, or -$4.56 per diluted share. Operating activities generated -$9.2M of cash, leaving -$9.2M of free cash flow. At fiscal year end, Oragenics held $10.1M in total assets against $1.8M in total liabilities, including $4.4M of cash and equivalents.
Open the full interactive Oragenics financials → Quarterly statements, key ratios, valuation history and price charts.
Oragenics Key Stats
| Share Price | $0.45 |
|---|---|
| Market Cap | $2.0M |
| 52-Week Range | $0.45 – $1.39 |
| Shares Outstanding | 4.4 million (basic, 2026 Q2) |
Oragenics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | $86,987 | $131,521 | $37,653 | — | $0 |
| Operating Income | -$26.6M | -$15.8M | -$14.4M | -$20.9M | -$10.6M | -$9.4M |
| Pre-Tax Income | -$26.4M | -$15.7M | -$14.3M | -$20.7M | -$10.6M | -$10.0M |
| Income Tax | — | — | — | — | — | -$136,910 |
| Net Income | -$26.4M | -$15.7M | -$14.3M | -$20.7M | -$10.6M | -$9.8M |
| Diluted EPS | -$846.00 | -$252.00 | — | -$275.40 | -$48.00 | -$4.56 |
Oragenics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.1M | -$2.3M | -$2.2M | -$2.5M |
| Diluted EPS | -$1.96 | -$1.06 | -$0.51 | -$0.57 |
Oragenics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.6M | $27.3M | $11.4M | $3.5M | $864,840 | $4.4M |
| Current Assets | $18.0M | $27.7M | $14.3M | $3.9M | $1.5M | $10.1M |
| Total Assets | $18.7M | $28.2M | $14.8M | $5.0M | $1.5M | $10.1M |
| Current Liabilities | $1.3M | $1.4M | $1.6M | $1.8M | — | — |
| Total Liabilities | $1.8M | $1.7M | $1.7M | $1.8M | $1.7M | $1.8M |
| Shareholders' Equity | $16.8M | $26.5M | $13.0M | $3.2M | -$211,885 | $8.3M |
Oragenics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$17.0M | -$13.5M | -$15.2M | -$7.3M | -$8.6M | -$9.2M |
| Cash From Investing | — | -$43,876 | -$115,519 | -$936,284 | — | — |
| Cash From Financing | $16.3M | $23.1M | -$494,916 | $283,880 | $6.0M | $16.8M |
| Free Cash Flow | -$17.0M | -$13.5M | -$15.4M | -$7.4M | -$8.6M | -$9.2M |
Figures from Oragenics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Oragenics financials page for every line item.
Oragenics Company Profile
| Ticker | OGEN |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Lakewood Ranch, Florida |
| Incorporated in | Florida |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001174940 |
Frequently Asked Questions
What was Oragenics' revenue in fiscal 2025?
Oragenics (OGEN) reported revenue of $0 for fiscal 2025.
What is Oragenics' annual revenue history?
Oragenics' annual revenue by fiscal year: 2021: $86,987; 2022: $131,521; 2023: $37,653; 2025: $0.
What was Oragenics' net income in fiscal 2025?
Oragenics reported net income of -$9.8M for fiscal 2025.
What was Oragenics' earnings per share (EPS) in fiscal 2025?
Oragenics' diluted EPS was -$4.56 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Oragenics generate in fiscal 2025?
Oragenics generated -$9.2M of free cash flow in fiscal 2025.
What was Oragenics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Oragenics reported revenue of $0.
How many shares of Oragenics are outstanding?
Oragenics reported a weighted average of 4.4 million basic shares outstanding in 2026 Q2.
What is Oragenics' market cap?
Based on its latest closing price, Oragenics (OGEN) has a market capitalization of about $2.0M.
When does Oragenics' fiscal year end?
Oragenics' fiscal year end, as registered with the SEC, is December 31.
Where is Oragenics headquartered?
Oragenics lists its business address in Lakewood Ranch, Florida in its SEC filings.